Fragile X syndrome, or "Martin Bell syndrome," is an inherited disorder that causes symptoms similar to the autism spectrum and which in many cases also results in developmental mental disorders.
Fragile X syndrome is the most common inherited cause of autism and mental retardation. To this day, despite the efforts of pharmaceutical companies, there is still no drug approved for treatment. A new study suggests that cannabidiol (CBD) treatment may be effective for people with the syndrome.
Fragile X syndrome (SXF) is a dominant X-linked disorder caused by a mutation in the mental retardation of fragile X. Cannabidiol (CBD) is an exogenous phytocannabinoid with therapeutic potential for sufferers anxiety, disorders sleep and deficits cognitive, as well as for populations with endocannabinoid deficiencies, such as those who suffer from SXF (a genetic disease caused by a mutation in the X chromosome). The objective of this study was to provide a brief narrative review of recent literature on endocannabinoids and SXF and to present a case series describing three patients with SXF who were treated orally.
This study reveals the importance of exploring the therapeutic potential of CBD in the context of rigorous clinical trials.
Patients in the study were given oral solutions of CBD 32-63,9 mg orally. In two of the patients, symptoms worsened after stopping CBD and further improved after resuming treatment.
All three patients described in the case series exhibited functional benefits following the use of oral CBD solutions, including notable reductions in social exclusion and anxiety, as well as improved sleep, nutrition, motor coordination, language skills and sensory processing. Two of the patients described had a re-emergence of a number of symptoms of FXS after discontinuation of treatment.
Rather, pharmacotherapy is aimed at alleviating secondary symptoms of the disease, such as self-harm, aggression, depression and anxiety, and mainly includes antidepressants and antipsychotics.
“Previous studies have shown that many of the abnormal symptoms of fragile X syndrome are due to a lack of regulation of the endocannabinoid system and reduced stimulation of their receptors due to a lack of natural endocannabinoids for s' link to it. Studies have shown that consuming CBD increases levels endocannabinoid anandamide and of AG-2, thus reducing or even neutralizing one of the biological mechanisms of abnormal cell function in fragile X syndrome. "
Although a number of drugs have been developed to target particular systems (GABA agonists), CBD has the potential to produce a multifaceted effect for people with SXF due to its multiple benefits and mechanisms of action.